Back to Agenda
[V2-S3] Medical Affairs Activities from the Viewpoint of the Stakeholder
Session Chair(s)
Kihito Takahashi
Head of R&D/Medical Affairs Hub Japan, Swedish Orphan Biovitrium (SOBI) Japan, Japan
Medical Affairs has various responsibilities, including information activities performed in pursuit of “Launch Excellence” during the development, application for approval, approval, and launch process of a drug, building medical strategies, engaging with key opinion leaders, and responding to drug-related inquiries. These medical activities are separate from promotion and independent of marketing, but the role of Medical Affairs is not yet widely recognized in Japan, or even within the pharmaceutical industry. This session will provide expert lectures on the role and duties of Medical Affairs, including Launch Excellence activities and support of investigator-initiated clinical trials, what different stakeholders expect from them, and what issues may arise.
Speaker(s)
Kyoko Murakami, MD, PHD
Associate Department Manager, MA Immuno-Inflammation & Infectious Diseases Dept., GlaxoSmithKline K.K., Japan
The Activity of MA and the Role of Medical Doctor in a Pharmaceutical Company
Masuhiro Kato, PHD
Project Professor, Translational Research Initiative, The University of Tokyo Hosptial, Japan
The Expectations and Current Issues Surrounding MA Regarding Investigator Initiated Trials
Ikuo Miyamoto, MSC, MT, RPH
Taskforce Leader, PMS Department, Japan Pharmaceutical Manufacturers Association (JPMA), Japan
Expectations and Current Issues Surrounding MA
Have an account?